Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hospital Mater DeiBSP:MATD3 -1.78%83 Future 3-5Y EPS without NRI Growth Rate is 35.82 as of Sep. 10, 2026. GuruFocus rates BSP:MATD3 with a GF Score™ of 83/100 and a GF Value™ of R$5.70 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 200 Healthcare Providers & Services companies, Hospital Mater Dei ranks better than 82% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Hospital Mater Dei's Future 3-5Y EPS without NRI Growth Rate is 35.82.
Hospital Mater Dei (BSP:MATD3) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Hospital Mater Dei Future 3-5Y EPS without NRI Growth Rate Related Terms
BSP:MATD3 vs HCA, THC, EHC: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Medical Care Facilities subindustry, Hospital Mater Dei's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hospital Mater Dei Future 3-5Y EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Hospital Mater Dei's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Hospital Mater Dei's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 35.82 mean?
Hospital Mater Dei (BSP:MATD3) has a Future 3-5Y EPS without NRI Growth Rate of 35.82 as of Sep. 10, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Hospital Mater Dei and its competitors. According to the industry distribution chart, Hospital Mater Dei ranks #36 out of 200 companies in the Healthcare Providers & Services industry, placing it in the top 18%.
Is Hospital Mater Dei's Future 3-5Y EPS without NRI Growth Rate too high?
Hospital Mater Dei's current Future 3-5Y EPS without NRI Growth Rate is 35.82. The Healthcare Providers & Services industry median Future 3-5Y EPS without NRI Growth Rate is 17.27. Hospital Mater Dei's value of 35.82 is 107.5% above this industry median. Based on the distribution chart, Hospital Mater Dei ranks #36 out of 200 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Hospital Mater Dei has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hospital Mater Dei's Future 3-5Y EPS without NRI Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Hospital Mater Dei ranks #36 out of 200 companies for Future 3-5Y EPS without NRI Growth Rate. This places Hospital Mater Dei in the top 18% of its industry — outperforming the majority of peers. The industry median Future 3-5Y EPS without NRI Growth Rate is 17.27. Hospital Mater Dei's value of 35.82 is 107.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median Future 3-5Y EPS without NRI Growth Rate among Healthcare Providers & Services companies is 17.27, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hospital Mater Dei's current Future 3-5Y EPS without NRI Growth Rate of 35.82 is 107.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Hospital Mater Dei and its competitors. For the Healthcare Providers & Services industry, the median Future 3-5Y EPS without NRI Growth Rate is 17.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hospital Mater Dei's current Future 3-5Y EPS without NRI Growth Rate is 35.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hospital Mater Dei stock overvalued right now?
Based on GuruFocus' analysis, Hospital Mater Dei (BSP:MATD3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$5.70, compared to a current price of R$4.98 — trading 12.6% below its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 35.82 and 107.5% above the Healthcare Providers & Services industry median of 17.27. Hospital Mater Dei's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Hospital Mater Dei (BSP:MATD3), the current Future 3-5Y EPS without NRI Growth Rate is 35.82 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hospital Mater Dei (BSP:MATD3) Overvalued in 2026?
Based on GuruFocus' analysis, Hospital Mater Dei stock appears to be undervalued.
The current stock price of R$4.98 is trading 12.6% below its estimated GF Value™ of R$5.70.
GuruFocus considers Hospital Mater Dei to be Modestly Undervalued.
Key valuation signals for BSP:MATD3:
Future 3-5Y EPS without NRI Growth Rate: 35.82
GF Value™: R$5.70 vs. price of R$4.98 (12.6% below fair value)
Industry Position: 107.5% above the Healthcare Providers & Services median (#36 of 200)
No single metric tells the full story. See the BSP:MATD3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hospital Mater Dei SA is an integrated healthcare ecosystem that provides hospital and oncological services. The company provides a wide range of healthcare services, including hospitalizations, surgeries, oncology treatments, medical appointments, and diagnostic exams.
83GF Score
Get the complete analysis for BSP:MATD3
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:MATD3 has been successfully added to your 
